Polymyalgia Rheumatica Market

Market Overview: 

The 7 major polymyalgia rheumatica markets reached a value of US$ 3,287.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 12,677.8 Million by 2034, exhibiting a growth rate (CAGR) of 13.06% during 2024-2034.

The polymyalgia rheumatica market has been comprehensively analyzed in IMARC's new report titled "Polymyalgia Rheumatica Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polymyalgia rheumatica refers to an inflammatory condition that causes muscle stiffness and pain, especially in the hips and shoulders. The common symptoms of this ailment include mild fever, fatigue, a general feeling of not being well, lack of appetite, unintended weight loss, depression, etc. Individuals suffering from polymyalgia rheumatica may also experience several indications, such as aches in the neck, upper arms, buttocks, or thighs, stiffness in the affected regions, particularly after being inactive for a time or in the morning, limited range of motion, etc. The diagnosis of this disease is based on a review of the patient’s symptoms, medical history, and physical examination. Numerous blood tests, including complete blood count (CBC), C-reactive protein, erythrocyte sedimentation rate, etc., are also utilized to confirm a diagnosis. The healthcare provider may perform several imaging studies, including MRI and ultrasound, for the evaluation of underlying indications.

The rising prevalence of several risk factors, such as genetic predisposition, chronic infections, environmental aspects, etc., is primarily driving the polymyalgia rheumatica market. In addition to this, the expanding geriatric population, who are more prone to immune dysfunction due to the reduced ability of producing new T cells, is also bolstering the market growth. Moreover, the widespread adoption of effective corticosteroids, including prednisolone which blocks the effects of specific chemicals in the body to decrease inflammation and enhance tissue growth and repair, is creating a positive outlook for the market. Apart from this, the inflating application of physical therapy to improve strength and increase the range of motion in patients is further propelling the market growth. Additionally, various key players are investing in extensive R&D activities to launch novel regimens that promote muscle flexibility and offer better bone health. This, in turn, is also acting as another significant growth-inducing factor. Moreover, the emerging popularity of subcutaneous sarilumab injection in disease treatment, since it works by blocking the interleukin-6 activity, a substance that causes inflammation in the body, is expected to drive the polymyalgia rheumatica market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the polymyalgia rheumatica market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for polymyalgia rheumatica and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polymyalgia rheumatica market in any manner.

Recent Developments:

• In June 2024, Sparrow Pharmaceuticals stated findings from an ongoing Phase 2 clinical trial of HSD-1 inhibitor clofutriben (SPI-62) and prednisolone in individuals with polymyalgia rheumatica at the 2024 Annual European Alliance for Associations for Rheumatology that indicate HSD-1 inhibition can allow for efficient treatment with glucocorticoid medications with fewer side effects.

Key Highlights:

• In the United States, the average yearly incidence of this illness is 52.5 cases per 100,000 people aged 50 and above.
• The prevalence is about 0.5-0.7 percent.
• In Europe, the frequency declines from north to south, with a high incidence in Scandinavia and a low level of incidence in Mediterranean countries.
• A United Kingdom study reported an overall incidence rate of 95.9 incidents per 100,000 people.
• White people are more affected than other ethnic groupings. polymyalgia rheumatica is only rarely observed among Blacks.
• Polymyalgia rheumatica is twice as prevalent in women.

Drugs:

RAYOS (prednisone controlled-release) is an anti-inflammatory medication used to treat a variety of disorders, including rheumatologic diseases such rheumatoid arthritis and polymyalgia rheumatica. RAYOS releases the prednisone dose in around 4 hours.

Tocilizumab is a recombinant humanized monoclonal antibody interleukin 6 (IL-6) receptor inhibitor used to treat inflammatory and autoimmune disorders. The drug has a long duration of effect because it is typically administered every four weeks and has a broad therapeutic index. It binds to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated inflammation.

Abatacept is a soluble fusion protein created using recombinant DNA technological procedure in Chinese hamster ovary cells. It is available in two forms: a subcutaneous solution and a powder concentrate solution for intravenous delivery. It is being developed to treat patients suffering from polymyalgia rheumatica.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the polymyalgia rheumatica market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the polymyalgia rheumatica market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current polymyalgia rheumatica marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the polymyalgia rheumatica market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the polymyalgia rheumatica market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the polymyalgia rheumatica market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of polymyalgia rheumatica across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of polymyalgia rheumatica by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of polymyalgia rheumatica by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with polymyalgia rheumatica across the seven major markets?
• What is the size of the polymyalgia rheumatica patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of polymyalgia rheumatica?
• What will be the growth rate of patients across the seven major markets?
   

Polymyalgia Rheumatica: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for polymyalgia rheumatica drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polymyalgia rheumatica market?
• What are the key regulatory events related to the polymyalgia rheumatica market?
• What is the structure of clinical trial landscape by status related to the polymyalgia rheumatica market?
• What is the structure of clinical trial landscape by phase related to the polymyalgia rheumatica market?
• What is the structure of clinical trial landscape by route of administration related to the polymyalgia rheumatica market?